Skip to content

Released Aug 1, 2019, after the close

10-Q filed Aug 7, 2019, 38 days after period end · 0001162194-19-000068

Q2 2019 · 10-Q
Revenue$28.20M+6.7% vs Q2 2018−6.4% vs Q1 2019
Net Income-$13.75MN/M vs Q2 2018N/M vs Q1 2019
EPS Diluted-$0.20N/M vs Q2 2018N/M vs Q1 2019
Gross Profit$15,363,000+13.1%
Operating Income-$14,636,000N/M
Operating Cash Flowderived-$5,013,000N/M
Free Cash Flowderived-$5,432,000N/M
Margins · derived
Gross margin54.5%+3.1 pt vs Q2 2018
Operating margin-51.9%−3.5 pt vs Q2 2018
Net margin-48.8%+12.7 pt vs Q2 2018

What the release said

The release

Same quarter

MetricQ2 2019Q2 2018Q2 2017Q2 2016
Revenue$28.20M$26.43M$23.91M$28.17M
Net Income-$13.75M-$16.24M-$16.93M-$18.62M
EPS Diluted-$0.20-$0.42-$0.58-$0.64

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR